Robert Negrin

Back to Profile

Publication Details

  • Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.

    Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL. Ann Intern Med. 1989; 110 (12): 976-84

    To determine the hematopoietic effects and toxicity of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with myelodysplastic syndromes.

    PubMedID: 2471429

Stanford Medicine Resources:

Footer Links: